Profile data is unavailable for this security.
About the company
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-151.16m
- Incorporated2020
- Employees89.00
- LocationALX Oncology Holdings Inc323 Allerton AvenueSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 466-7125
- Fax+1 (302) 655-5049
- Websitehttps://alxoncology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omega Therapeutics Inc | 6.31m | -78.90m | 62.88m | 93.00 | -- | 2.39 | -- | 9.96 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| RetinalGenix Technologies Inc | 0.00 | -4.04m | 62.99m | 0.00 | -- | -- | -- | -- | -0.2291 | -0.2291 | 0.00 | -0.101 | 0.00 | -- | -- | -- | -9,059.05 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -1,050.46 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Champions Oncology Inc | 51.66m | -3.40m | 63.08m | 210.00 | -- | -- | -- | 1.22 | -0.2541 | -0.2541 | 3.78 | -0.0244 | 1.88 | -- | 5.75 | 245,976.20 | -12.39 | -10.00 | -44.43 | -23.00 | 44.27 | 46.58 | -6.58 | -6.04 | -- | -- | 333.00 | -- | -6.90 | 13.13 | -36.38 | -- | 0.0479 | -- |
| Prelude Therapeutics Inc | 3.00m | -131.52m | 63.29m | 128.00 | -- | 0.3101 | -- | 21.10 | -1.77 | -1.77 | 0.0404 | 3.71 | 0.0132 | -- | -- | 23,437.50 | -57.72 | -47.21 | -63.14 | -51.07 | -- | -- | -4,383.90 | -- | -- | -- | 0.0023 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Aligos Therapeutics Inc | 7.97m | -75.74m | 64.04m | 68.00 | -- | 1.67 | -- | 8.04 | -25.99 | -25.99 | 1.89 | 10.70 | 0.0741 | -- | -- | 120,712.10 | -70.47 | -51.20 | -92.27 | -59.73 | -- | -- | -950.61 | -1,399.21 | -- | -- | 0.0031 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Precision BioSciences Inc | 75.10m | 11.48m | 64.21m | 108.00 | 10.95 | 0.9653 | 4.09 | 0.855 | 0.7641 | 0.0524 | 12.85 | 8.67 | 0.4729 | -- | 29.70 | 688,954.10 | 7.23 | -35.35 | 9.00 | -44.22 | -- | -- | 15.28 | -147.50 | -- | -- | 0.2557 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
| Atara Biotherapeutics Inc | 62.39m | -181.05m | 66.09m | 165.00 | -- | -- | -- | 1.06 | -39.90 | -39.90 | 13.06 | -22.61 | 0.343 | 0.931 | 42.60 | 277,275.60 | -99.55 | -70.20 | -256.98 | -86.94 | 80.14 | -- | -290.20 | -1,559.33 | 0.2945 | -250.76 | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Agenus Inc | 159.63m | -223.67m | 66.98m | 389.00 | -- | -- | -- | 0.4196 | -11.27 | -11.27 | 8.03 | -11.42 | 0.4723 | -- | 154.98 | 410,357.30 | -68.45 | -55.02 | -281.52 | -115.31 | 99.51 | -- | -144.94 | -102.92 | -- | -0.9185 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Vor Biopharma Inc | 0.00 | -112.46m | 67.97m | 168.00 | -- | 0.9315 | -- | -- | -1.65 | -1.65 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -66.35 | -45.79 | -72.73 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| VolitionRX Ltd | 976.52k | -32.42m | 68.89m | 110.00 | -- | -- | -- | 70.55 | -0.4032 | -0.4032 | 0.0121 | -0.263 | 0.0481 | -- | 5.38 | 8,877.45 | -161.39 | -111.92 | -- | -196.20 | -- | -- | -3,357.34 | -10,793.31 | -- | -129.66 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| ALX Oncology Holdings Inc | 0.00 | -151.16m | 70.58m | 89.00 | -- | 0.5166 | -- | -- | -2.98 | -2.98 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -74.50 | -34.34 | -89.35 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0851 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Spero Therapeutics Inc | 118.46m | 17.46m | 71.34m | 46.00 | 4.17 | 0.8856 | 4.05 | 0.6023 | 0.3169 | 0.3169 | 2.21 | 1.49 | 0.9524 | -- | 4.11 | 2,575,196.00 | 14.03 | -35.52 | 18.79 | -41.75 | -- | -- | 14.74 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -53.12m | 72.70m | 32.00 | -- | 1.55 | -- | -- | -1.27 | -1.27 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -47.50 | -42.72 | -50.26 | -46.06 | -- | -- | -- | -- | -- | -- | 0.2275 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Syros Pharmaceuticals Inc | 386.00k | -97.82m | 73.25m | 68.00 | -- | -- | -- | 189.77 | -3.03 | -3.03 | 0.0105 | -0.4145 | 0.0033 | -- | -- | 5,676.47 | -84.04 | -54.44 | -111.15 | -64.32 | -- | -- | -25,340.67 | -772.82 | -- | -179.01 | 1.37 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Beyondspring Inc | 1.88m | -15.57m | 74.96m | 35.00 | -- | -- | -- | 39.96 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Aerovate Therapeutics Inc | 0.00 | -87.94m | 76.79m | 51.00 | -- | 0.8131 | -- | -- | -3.14 | -3.14 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -65.76 | -- | -74.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
Data as of Nov 13 2024. Currency figures normalised to ALX Oncology Holdings Inc's reporting currency: US Dollar USD
55.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 7.77m | 14.75% |
| Tang Capital Management LLCas of 12 Aug 2024 | 4.04m | 7.67% |
| Redmile Group LLCas of 30 Jun 2024 | 4.04m | 7.66% |
| Vestal Point Capital LPas of 30 Jun 2024 | 3.60m | 6.84% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 2.36m | 4.48% |
| Millennium Management LLCas of 30 Sep 2024 | 2.00m | 3.80% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.63m | 3.10% |
| Paradigm BioCapital Advisors LPas of 30 Jun 2024 | 1.58m | 2.99% |
| HBM Partners AG (Investment Management)as of 31 Mar 2024 | 1.50m | 2.85% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 705.55k | 1.34% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
